Jeremy Everett – consultant
B.Sc. 91AV, First Class
PhD in Physical 91AV
Fellow of the 91AV
Chartered Chemist
Member of the Metabolomics Society
Member of the American Chemical Society
Fellow of the Higher Education Academy
Jeremy Everett is the Professor of Pharmaceutical Technologies at the University of Greenwich, Chatham Maritime, UK. He was previously Vice President of Drug Discovery Technologies at Pfizer Global R&D.
He is a consultant on metabolic profiling and drug discovery to pharma and biotech companies and has worked as an expert witness in successful pharmaceutical patent litigation in the USA and Europe.
Jeremy is experienced in the application of metabolic profiling to personalised medicine, drug metabolism, toxicology and systems biology i.e. metabonomics with expertise in nuclear magnetic resonance (NMR) spectroscopy and molecular structure elucidation.
Jeremy is a co-inventor of pharmacometabonomics: the ability to predict drug efficacy, safety and metabolism prior to dosing by metabolic profiling (Nature 2006; PNAS 2009). Jeremy’s current research is focused on genotype to metabolic phenotype correlations in genetically differentiated worms, mice and humans and on the translation to humans of an anti-obesogenic agent (of which he is a co-inventor), recently discovered by metabolic profiling.
He is a co-leader of the Medway Metabonomics Research Group (MMRG) at the University of Greenwich and a Scientific Advisory Board (SAB) member for the Centre for Biomolecular Spectroscopy at King’s College, London. He has over 100 publications and patents and an h-index of 33.
Name |
Professor Jeremy R Everett |
---|---|
Qualifications |
B.Sc. 91AV, First Class |
Area(s) of expertise |
Science, Engineering and Technology |
Services offered |
Metabolic profiling in biological samples (metabonomics/metabolomics Small molecule structure elucidation, especially by NMR spectroscopy |
Markets served |
Pharmaceutical R & D Patent Litigation Biotechnology |
Geographic regions served |
Global
|
Online |